Bortezomib
Clinical data | ||
---|---|---|
Trade names | Velcade, Chemobort, Bortecad, others | |
Other names | PS-341 | |
AHFS/Drugs.com | Monograph | |
MedlinePlus | a607007 | |
License data |
| |
Pregnancy category |
| |
Routes of administration | Subcutaneous, intravenous | |
ATC code | ||
Legal status | ||
Legal status | ||
JSmol) | ||
| ||
| ||
(verify) |
Bortezomib, sold under the brand name Velcade among others, is an
Common side effects include nausea, diarrhea, tiredness,
Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004.
Medical use
Two open-label trials established the efficacy of bortezomib (with or without
Bortezomib was also evaluated together with other drugs for the treatment of multiple myelomas in adults. It was seen that bortezomib plus lenalidomide plus dexamethasone as well as bortezomib plus melphalan and prednisone may result in a large increase in the progression-free survival.[8]
Adverse effects
Ocular side effects such as chalazion or hordeolum (stye) may be more common in women and have led to discontinuation of treatment.[12] Acute interstitial nephritis has also been reported.[13]
Drug interactions
Polyphenols derived from green tea extract including epigallocatechin gallate (EGCG), which were expected to have a synergistic effect, instead were found to reduce the effectiveness of bortezomib in cell culture experiments.[14]
Pharmacology
Structure
The drug is an N-protected dipeptide and can be written as Pyz-Phe-boroLeu, which stands for pyrazinoic acid, phenylalanine and Leucine with a boronic acid instead of a carboxylic acid.
Mechanism
The boron atom in bortezomib is proposed to bind the catalytic site of the 26S proteasome[15] with high affinity and specificity. In normal cells, the proteasome regulates protein expression and function by degradation of ubiquitylated proteins, and also rids the cell of abnormal or misfolded proteins. Clinical and preclinical data support a role for the proteasome in maintaining the immortal phenotype of myeloma cells, and cell-culture and xenograft data support a similar function in solid tumor cancers. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent degradation of pro-apoptotic factors, thereby triggering programmed cell death in neoplastic cells. Bortezomib causes a rapid and dramatic change in the levels of intracellular peptides that are produced by the proteasome.[16] Some intracellular peptides have been shown to be biologically active, and so the effect of bortezomib on the levels of intracellular peptides may contribute to the biological and/or side effects of the drug.
Pharmacokinetics and pharmacodynamics
After subcutaneous administration, peak plasma levels are ~25-50 nM and this peak is sustained for 1-2 hrs. After intravenous injection, peak plasma levels are ~500 nM but only for ~5 minutes, after which the levels rapidly drop as the drug distributes to tissues (volume of distribution is ~500 L).[17][18] Both routes provide equal drug exposures and generally comparable therapeutic efficacy. Elimination half life is 9–15 hours and the drug is primarily cleared by hepatic metabolism.[19]
The pharmacodynamics of bortezomib are determined by quantifying proteasome inhibition in peripheral blood mononuclear cells taken from people receiving the drug.
History
Bortezomib was originally made in 1995 at Myogenics. The drug (PS-341) was tested in a small Phase I clinical trial on people with
In May 2003, seven years after the initial synthesis, bortezomib (marketed as Velcade by Millennium Pharmaceuticals Inc.) was approved in the United States by the Food and Drug Administration (FDA) for use in multiple myeloma, based on the results from the SUMMIT Phase II trial.[21][22] In 2008, bortezomib was approved in the United States for initial treatment of people with multiple myeloma.[23] Bortezomib was previously approved in 2005, for the treatment of people with multiple myeloma who had received at least one prior therapy and in 2003, for the treatment of more refractory multiple myeloma.[23]
The 2008 approval was based on an international, multicenter, open label, active-control trial in previously untreated people with symptomatic multiple myeloma.[23] People were randomized to receive either nine cycles of oral melphalan (M) plus prednisone (P) or MP plus bortezomib.[23] People received M (9 mg/m2 ) plus prednisone (60 mg/m2 ) daily for four days every 6 weeks or the same MP schedule with bortezomib, 1.3 mg/m2 iv on days 1, 8, 11, 22, 25, 29, and 32 of every 6 week cycle for 4 cycles then once weekly for 4 weeks for 5 cycles.[23] Time- to- progression (TTP) was the primary efficacy endpoint.[23] Overall survival (OS), progression-free survival (PFS), and response rate (RR) were secondary endpoints.[23] Eligible people were age > 65 years.[23] A total of 682 people were randomized: 338 to receive MP and 344 to the combination of bortezomib plus MP.[23] Demographics and baseline disease characteristics were similar between the two groups.[23]
The trial was stopped following a pre-specified interim analysis showing a statistically significant improvement in TTP with the addition of bortezomib to MP (median 20.7 months) compared with MP (median 15 months) [HR: 0.54 (95% CI: 0.42, 0.70), p= 0.000002].[23] OS, PFS, and RR also were significantly superior for the bortezomib-MP combination.[23]
In August 2014, bortezomib was approved in the United States for the retreatment of adults with multiple myeloma[24][25] who had previously responded to Velcade therapy and relapsed at least six months following completion of prior treatment.[25]
In October 2014, bortezomib was approved in the United States for the treatment of treatment-naïve people with mantle cell lymphoma (MCL).[25]
Society and culture
Economics
In the UK,
See also
- Ixazomib, a proteasome inhibitor that is given by mouth
- Peter Elliott (pharmacologist)
References
- ^ Baxter Healthcare Pty Ltd
- ^ a b c d e f "Bortezomib Monograph for Professionals". Drugs.com. Retrieved 13 October 2019.
- ^ a b c d e "Velcade". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
- ^ PMID 19441872. Archived from the originalon 8 October 2011. Retrieved 26 March 2010.
- S2CID 195357104.
- PMID 31765002.
- ^ "Highlights Of Prescribing Information" (PDF). Archived from the original (PDF) on 19 February 2009. Retrieved 19 December 2022.
- S2CID 34591121.
- PMID 19406726.
- PMID 30575098.
- PMID 26109684.
- PMID 19190249.
- PMID 17268529.
- PMID 23308178.
- PMID 20306195.
- PMID 14695130.
- PMID 21507715.
- S2CID 53301933.
- S2CID 23644211.
- ^ "Drug Approval Package: Velcade (Bortezomib) NDA #021602". U.S. Food and Drug Administration (FDA). 13 May 2003. Archived from the original on 5 December 2019. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.
- ^ a b c d e f g h i j k l "Velcade (bortezomib) is Approved for Initial Treatment of Patients with Multiple Myeloma" (Press release). U.S. Food and Drug Administration (FDA). 23 June 2008. Archived from the original on 1 December 2011. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.
- ^ "Millennium: The Takeda Oncology Company". .millennium.com. 8 August 2014. Archived from the original on 1 November 2018.
- ^ PMID 26629279.
- ^ "NHS watchdog rejects cancer drug". BBC News Online. 20 October 2006. Retrieved 14 August 2009.
- ^ "Summary of Velcade Response Scheme" (PDF). Archived from the original (PDF) on 19 April 2009. Retrieved 14 August 2009.
- ^ "More Velcade-Style Risk-Sharing In The UK?". Euro Pharma Today. 21 January 2009. Archived from the original on 10 July 2011. Retrieved 14 August 2009.
External links
- "Bortezomib". Drug Information Portal. U.S. National Library of Medicine.
- "Bortezomib". NCI Drug Dictionary. National Cancer Institute.
- "Bortezomib". National Cancer Institute. 5 October 2006.